Home > Algemeen > Wetenschap > AEG33773

AEG33773

AEG33773 is een nieuw molecuul uit de klasse van de zogenaamde heat-shock eiwitten, in ontwikkeling voor neuropathische pijn. De stof is momenteel in zogenaamde fase II (dose finding). Er is nog niets over dit molecuel gepubliceerd, behalve wat de firma kwijt wil erover. Die firma meldde in 2009 over de status van ontwikkeling:

AEG33773 is a first-in-class oral small molecule allosteric HSP90 modulator/JNK pathway inhibitor. It is efficacious in multiple preclinical models of neuropathic and inflammatory pain and has demonstrated exceptional efficacy with sustained pain relief over a much longer period in preclinical models of diabetic neuropathic pain (allodynia). A multiple dose Phase I trial was successfully completed.

Aegera is currently testing AEG33773 in a randomized, placebo-controlled Phase 2a proof-of-concept study in diabetic patients suffering from painful neuropathy. The study is ongoing in Canada, the United States and Europe.

December 2009, prof.dr. Jan M. Keppel Hesselink

Gerelateerde artikelen